Pulmonary vascular disease & thromboembolism
Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system
Authors' conclusion
Our approach and results, which may be adapted to other European healthcare systems, provide a benchmark for healthcare costs expected to result from CDT.
Study context
- Population
- Patients hospitalised with severe (intermediate- or high-risk) pulmonary embolism (PE); US trends applied to forecast PE-related hospitalisations in Germany, 2025–30
- Comparison
- National Inpatient Sample (NIS)-based vs PERT-based model of catheter-directed treatment (CDT) uptake
- Outcome
- Proportion of CDT among all hospitalisations with PE
- Follow-up
- 2030
Main finding
As reported in the abstract
CDT proportion among all PE hospitalisations
Further findings
Increase in annual costs of PE-related hospitalisations in Germany · by 2030
- Estimated increase in annual costs, based on current reimbursement rates
- 15.3 to 49.8 million euros
- Does not account for potential cost savings, including reduced length of stay
Original publication
Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system. Eur Heart J Acute Cardiovasc Care. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →